Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes
…, M Ezrokhi, D Rutty, ZJ Ma, RE Scranton - Diabetes …, 2010 - Am Diabetes Assoc
OBJECTIVE Quick-release bromocriptine (bromocriptine-QR), a D2 dopamine receptor
agonist, is indicated as a treatment for type 2 diabetes. The Cycloset Safety Trial, a 52-week, …
agonist, is indicated as a treatment for type 2 diabetes. The Cycloset Safety Trial, a 52-week, …
The association between statins and cancer incidence in a veterans population
WR Farwell, RE Scranton, EV Lawler… - Journal of the …, 2008 - academic.oup.com
Background Meta-analyses of trials of 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors
or statins for cardiovascular disease prevention have failed to show any statistically …
or statins for cardiovascular disease prevention have failed to show any statistically …
Statins and prostate cancer diagnosis and grade in a veterans population
WR Farwell, LW D'Avolio, RE Scranton… - Journal of the …, 2011 - academic.oup.com
Background Although prostate cancer is commonly diagnosed, few risk factors for high-grade
prostate cancer are known and few prevention strategies exist. Statins have been …
prostate cancer are known and few prevention strategies exist. Statins have been …
Statin use and fracture risk: study of a US veterans population
RE Scranton, M Young, E Lawler… - Archives of internal …, 2005 - jamanetwork.com
Background Whether statins reduce the risk of fractures is still contested. Several studies
support a favorable association, whereas post hoc analyses of statin-randomized trials have …
support a favorable association, whereas post hoc analyses of statin-randomized trials have …
Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management
RE Scranton, I Goldstein… - The journal of sexual …, 2013 - academic.oup.com
Introduction Optimal pharmacologic management of diseases comorbid with erectile dysfunction
(ED), such as cardiovascular disease, depression, diabetes, dyslipidemia, hypertension…
(ED), such as cardiovascular disease, depression, diabetes, dyslipidemia, hypertension…
[HTML][HTML] Timed bromocriptine-QR therapy reduces progression of cardiovascular disease and dysglycemia in subjects with well-controlled type 2 diabetes mellitus
…, JM Gaziano, L Blonde, A Vinik, RE Scranton… - Journal of Diabetes …, 2015 - hindawi.com
Background. Type 2 diabetes (T2DM) patients, including those in good glycemic control,
have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic control …
have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic control …
[HTML][HTML] A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either …
RE Scranton, JM Gaziano, D Rutty, M Ezrokhi… - BMC endocrine …, 2007 - Springer
Background Cycloset™ is a quick-release formulation of bromocriptine mesylate, a dopamine
agonist, which in animal models of insulin resistance and type 2 diabetes acts centrally to …
agonist, which in animal models of insulin resistance and type 2 diabetes acts centrally to …
Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents
AI Vinik, AH Cincotta, RE Scranton, N Bohannon… - Endocrine Practice, 2012 - Elsevier
… Scranton has served within the past five years as consultant or advisor for Berlex, Sanofi-Aventis,
and a lecturer for KOS; a scientific investigator for Pfizer Inc, Merck, Pliva, Berlex …
and a lecturer for KOS; a scientific investigator for Pfizer Inc, Merck, Pliva, Berlex …
Effect of treating erectile dysfunction on management of systolic hypertension
RE Scranton, E Lawler, M Botteman… - The American journal of …, 2007 - Elsevier
Erectile dysfunction (ED) is a prevalent condition and a predictor of future cardiovascular
events. Screening and treatment of ED may improve management of cardiovascular risk factors…
events. Screening and treatment of ED may improve management of cardiovascular risk factors…
Cardiovascular benefit of magnitude of low-density lipoprotein cholesterol reduction: a comparison of subgroups by age
CR Rahilly-Tierney, EV Lawler, RE Scranton… - Circulation, 2009 - Am Heart Assoc
Background— We examined the effect of the magnitude of low-density lipoprotein cholesterol
(LDL-C) reduction across subjects of various ages in a retrospective cohort study. Methods …
(LDL-C) reduction across subjects of various ages in a retrospective cohort study. Methods …